CONCLUSION:
Clinicians should consider the potential association of Daunorubicin
with SJS, administer it with caution and observe patients closely for
potentially dangerous cutaneous reaction and treat it as an oncologic
emergency. If multi-drug regimen chemotherapy is employed, one must
administer the drugs with caution and all subsequently developing
cutaneous reactions must promptly be evaluated with a high index of
suspicion for SJS.